Stem cell company Arteriocyte has received U.S. Food and Drug Administration approval to begin a phase 1 clinical trial that will treat soldiers at risk for compartment syndrome.
Compartment syndrome is a serious condition that involves a buildup of fluid pressure in soft tissue compartments within the body. It’s caused by trauma and can lead to amputation.
The trial will involve Cleveland-based Arteriocyte’s Magellan FDA-cleared medical device, which harvests and quickly concentrates stem cells and blood platelets during surgeries, according to a statement from the company. These concentrated cells can be injected into patients and boost the body’s ability to repair itself.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The study will be performed at Ohio State University Wexner Medical Center.
Arteriocyte has partnered with the U.S. military to develop the technology for three therapeutic areas: extremity trauma, burn wounds and infection prevention. It received FDA approval to begin a phase 1 critical limb ischemia trial last year.
[Photo from flickr user The U.S. Army]
